Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.56 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | BCR | P11274 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18297270 | 0.92 | TLR8 (0.47) | TLR8TLR7HPGDMAPK1TSHR | |
| SCHEMBL1093907 | 0.83 | TLR8 (0.47) | TLR8TLR7HPGDMAPK1TSHR | |
| SCHEMBL233011 | 0.83 | EGFR (0.41) | TLR8TLR7TSHR | |
| SCHEMBL233870 | 0.82 | TLR8 (0.36) | TLR8TLR7SMN1; SMN2NPC1RAB9A | |
| SCHEMBL28810372 | 0.79 | TLR8 (0.45) | TLR8TLR7HPGDMAPK1TSHR | |
| SCHEMBL1094511 | 0.77 | TLR8 (0.71) | TLR8TLR7HPGDMAPK1TSHR | |
| SCHEMBL1238138 | 0.76 | TLR8 (0.69) | TLR8TLR7HPGDMAPK1TSHR | |
| SCHEMBL1901277 | 0.75 | TLR8 (0.44) | TLR8TLR7HPGDTSHRMEN1 | |
| SCHEMBL28145441 | 0.75 | TLR8 (0.43) | TLR8TLR7HPGDMAPK1TSHR | |
| SCHEMBL1802374 | 0.74 | TLR8 (0.73) | TLR8TLR7HPGDMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940797-B1 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | ARRAY BIOPHARMA INC (US) | 2012-08-01 | — | — | EP | claimed |
| EP-2940009-B1 | METHODS OF SYNTHESIS OF BENZAZEPINE DERIVATIVES | VENTIRX PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-2940009-A1 | METHODS OF SYNTHESIS OF BENZAZEPINE DERIVATIVES | VentiRx Pharmaceuticals, Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2358683-B1 | METHODS OF SYNTHESIS OF BENZAZEPINE DERIVATIVES | VENTIRX PHARMACEUTICALS INC (US) | 2015-04-01 | — | — | EP | disclosed |
| US-8314090-B2 | Methods of synthesis of benzazepine derivatives | VENTIRX PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20100216989-A1 | METHODS OF SYNTHESIS OF BENZAZEPINE DERIVATIVES | VENTIRX PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216989-A1 | METHODS OF SYNTHESIS OF BENZAZEPINE DERIVATIVES | MAOB, GABBR1, HNMT | TLR8 4758/4885TLR7 4486/4885HPGD 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.